Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
02 juin 2022 07h00 HE
|
Clene, Inc.
SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
01 juin 2022 07h00 HE
|
Clene, Inc.
New interim survival data from the ongoing RESCUE-ALS long-term open label extension (OLE) study demonstrate that early treatment (original randomization to active CNM-Au8) decreased risk of mortality...
Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility
19 mai 2022 07h30 HE
|
Clene, Inc.
$3 million 60-month loan to support capital equipment purchases in new 75,000-square-foot facility in Elkton, Maryland, for manufacture of Clene’s lead drug candidate, CNM-Au8®, for treatment of ALS ...
Clene to Present at Upcoming Investor Conferences
16 mai 2022 08h00 HE
|
Clene, Inc.
SALT LAKE CITY, May 16, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
09 mai 2022 08h00 HE
|
Clene, Inc.
Cash, cash equivalents, restricted cash and marketable securities of $36.6 million as of March 31, 2022Additional data from RESCUE-ALS presented at 2022 AAN Annual Meeting and MDA Clinical &...
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
01 avr. 2022 07h00 HE
|
Clene, Inc.
SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference
14 mars 2022 07h00 HE
|
Clene, Inc.
Analyses of long-term open-label extension of RESCUE-ALS trial indicate improved survival compared to predictions derived from validated ENCALS risk modelInterim results demonstrate approximately 70%...
Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
11 mars 2022 07h00 HE
|
Clene, Inc.
Cash and restricted cash of $50.3 million as of December 31, 2021Visionary-MS Phase 2 Trial unblinded results expected 2H 2022Healey ALS Platform Trial top-line data expected 2H 2022COVID-19 Phase 2...
Clene Nanomedicine to Present at Upcoming Investor Conferences
03 mars 2022 07h00 HE
|
Clene, Inc.
SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
24 févr. 2022 07h00 HE
|
Clene, Inc.
VISIONARY-MS Phase 2 blinded interim data suggest clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatment REPAIR-MS Phase 2...